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Background: Recent neonatal screening for isovaleric acidemia by tandem mass 
spectrometry based on dried blood spot levels of C5-acylcarnitines, including 
isovalerylcarnitine and its isomer, pivaloylcarnitine, which is derived from pivalate-
generating antibiotics, has caused many false-positive results. We have developed a method 
to overcome this interference. 
Methods: The amounts of isovalerylglycine were determined by a stable-isotope dilution 
electrospray tandem mass spectrometric analysis, using multiple reaction monitoring with 
product ions of m/z 132, which were generated predominantly from quasi-molecular ions of 
isovalerylglycine butylester but apparently not from those of pivaloylglycine butylester.  
Results: Isovalerylglycine concentrations in dried blood spots of control newborns were 
0.17 ± 0.03 nmol/ml, and those of patients with isovaleric acidemia ranged from 1.3 to 80.0 
nmol/ml. Those of the newborns treated with antibiotics, which caused high C5-
acylcarnitine levels (1.9 ± 1.7 nmol/ml) in dried blood spots, were 0.22 ± 0.05 nmol/ml.  
Conclusions: Our data showed that the present method is useful in eliminating the false-

















     Isovaleric acidemia (IVA; McKusick 243500) is an autosomal recessive disorder 
caused by mutations in the isovaleryl-CoA dehydrogenase (EC 1.3.99.10) gene. The 
deficiency of this enzyme in the metabolism of leucine leads to the accumulation of a series 
of isovaleryl-CoA metabolites, such as 3-hydroxyisovaleric acid, isovalerylglycine (IVG) 
[1,2], and isovalerylcarnitine [3], in body fluids. There are three phenotypes, two classic 
forms of the severe neonatal-onset type and the milder chronic intermittent type, and a mild 
biochemical form, which has been identified in newborn screening by tandem mass 
spectrometry (MS-MS) [4]. In newborn screening for organic acidemias and fatty acid 
oxidation disorders, acylcarnitines in dried blood spots (DBS) are measured by flow-
injection electrospray ionization (ESI) MS-MS [5-7]. In this measurement, the isomers of 
isovalerylcarnitine as an indicator of IVA and pivaloylcarnitine, which is derived from 
pivalate-generating antibiotics (PGA), are not determined separately. Thus, the common 
usage of this kind of antibiotics with newborns resulted in a relatively high false-positive 
rate (0.5-1%) for IVA in Japan [8]. It is important to reduce false-positive results, which 
may place families at risk for increased stress [9]. To overcome this interference, we have 





2.1.1. Biological samples 
     The dried blood spots used in our pilot study of newborn screening by MS-MS were 
collected on the newborns’ fifth or sixth day of life, with the informed consent of their 
parents, using the same filter paper (Toyo Roshi, Tokyo, Japan) as that used in general 
neonatal screening in Japan [6]. 
     A Japanese patient with IVA was diagnosed prenatally because of his elder siblings 
with this disease [10]. The other three patients with IVA became symptomatic in their early 
infancy and were diagnosed by urinary organic acid analysis using gas chromatography-
mass spectrometry (GC-MS) and enzyme assay [11]. Frozen serum specimens and dried 
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blood spots were transferred to our laboratory and stored in a freezer until analysis. 
 
2.1.2. Chemicals 
     [2H2]glycine was purchased from Cambridge Isotope Laboratories (Andover, MA, 
USA). Isovaleryl chloride, pivaloyl chloride, 2-methylbutyric acid, thionylchloride, glycine, 
and HPLC-grade formic acid were purchased from Wako Pure Chemical Industries (Osaka, 
Japan). Acetyl chloride and n-butanol were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). HPLC-grade acetonitrile, methanol, and distilled water were purchased from Nacalai 
Tesque (Kyoto, Japan). IVG, [2H2]IVG, pivaloylglycine (PG), [2H2]PG, and 2-
methylbutyrylglycine (MBG) were synthesized according to the reported methods [12]. 
 
2.2. Methods 
2.2.1. Sample preparation 
     To the dried blood-spot punch (3.2 mm diameter) in a well of a microtiter plate, 110 
μl of 99% methanol solution containing 0.2 nmol/ml of [2H2]IVG was added, and the plate 
was agitated gently at room temperature for 15 min. The extract solution was transferred to 
a second plate and dried under a nitrogen stream. The dried residue was derivatized at 65˚C 
for 15 min using 3N HCl/butanol. The derivatized sample was dried under a nitrogen stream 
and dissolved in 80% acetonitrile solution with 0.05% formic acid. 
     For calibrators, aliquots of heparinized whole blood of a healthy adult were fortified 
with IVG at blood concentrations of 0.10, 0.25, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0, and 50 
nmol/ml, and each of the aliquots was spotted on the filter paper mentioned above. 
     To determine the recovery rate of IVG, the calibrator with 5 nmol/ml of IVG was 
extracted using 110 μl of methanol solution without [2H2]IVG, and the extract was 
transferred into a well containing 110 μl of methanol solution with [2H2]IVG and then 
processed using the method mentioned above. The values obtained were compared with 
those of the solution containing IVG and [2H2]IVG processed without extraction. 
     To determine the IVG concentrations in serum samples, the mixture of 5 μl of serum 
and 183 μl of 95% methanol solution containing 0.2 nmol/ml of [2H2]IVG was centrifuged 
at 10,000 x g for 10 min. The supernatant was dried under a nitrogen stream, and the dry 
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residue was derivatized as mentioned above. 
     The acylcarnitines and free carnitine in sera and DBS were measured according to the 
methods reported previously [6,8]. 
 
2.2.2. Tandem mass spectrometry conditions 
     A model API 4000 triple-stage mass spectrometer (Applied Biosystems, Tokyo, 
Japan) was used as an MS-MS system, equipped with a Turbo Ion Spray® as ESI. The 
heated gas temperature was 500˚C, and the ion source voltage was 5500eV. Using a model 
LC10Avp HPLC system and a model SIL-20AC auto-injector (Shimadzu, Kyoto, Japan), 
derivatized samples (13 μl) were injected at about 0.8-min intervals into a flow of the 
mixture of 95% methanol and 90% acetonitrile (1:1, v/v) with 0.05% formic acid. The flow 
rate was programmed as follows: 1.0 ml/min from 0 to 0.03 min, 0.05 ml/min from 0.04 to 
0.4 min, and 1.5 ml/min from 0.41 min. The mass spectrometer was operated using Analyst 
software version 1.4. The quadrupole operated at unit resolution. Suitable measurement 
conditions for designated transitions from precursor to product ions were identified with the 
automatic tune function of the Analyst software. The positive ion MS-MS was performed in 
multiple-reaction monitoring (MRM) mode with m/z 216 → 132 for IVG, m/z 216 → 142 
for IVG and PG, and m/z 218 → 134 for [2H2]IVG with declustering potential of 51 V, 
collision energy of 15 V, and collision cell exit potential of 8 V. Collision gas (nitrogen) 
parameter was the original value of the instrument. The data were recorded for 0.4 min after 
every sample injection. For quantification, the recorded intensities of the designated MRM 




     Figure 1 shows the product ion mass spectra of quasi-molecular ions (m/z 216) of 
derivatized IVG, MBG, and PG under the MS-MS conditions suitable for derivatized IVG 
mentioned above. The product ion m/z 132 was the highest, and that of m/z 142 was the 
second highest in intensity among those of quasi-molecular ions of derivatized IVG and 
MBG, while that of m/z 142 was the highest, and that of m/z 132 was markedly low among 
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those of quasi-molecular ions of derivatized PG. MRM chromatograms in the analysis of a 
patient with IVA and a newborn treated with PGA are shown in Fig. 2. The increased 
intensity of m/z 216 → 132 in the measurement of the patient sample demonstrated the 
accumulated isovalerylglycine. The increased intensity of m/z 216 → 142 indicated the 
accumulated PG in a newborn treated with PGA. Quantification was performed using 
averaged intensities of the designated MRM ion set. 
     The averaged intensity of MRM measurements with m/z 216 → 132 of methanol 
solution containing 0.2 nmol/ml of [2H2]IVG without extraction was 2.1 (± 0.2) x 102 cps, 
and those of DBS containing 0 and 0.1 nmol/ml of spiked IVG, extracted with methanol 
solution containing 0.2 nmol/ml of [2H2]IVG, were 3.2 (± 0.5) x 102 and 5.1 (± 0.4) x 102 
cps, respectively. The linearity of the calibration curve for spiked IVG in DBS was 
observed over the concentration range 0.10-50 nmol/ml: slope = 1.12, intercept = -0.14 in 
X-axis of the IVG value obtained using the intensity ratio. The mean recovery for IVG was 
87% at the concentration of 5 nmol/ml in calibrators. 
     The intra-assay variabilities were tested by the analysis of six samples processed at 
the same time, and the inter-assay variabilities were tested by processing and analyzing one 
sample on 6 different days, using the DBS calibrators. The coefficients of variation are 
listed in Table 1. 
     IVG concentrations in DBS of the patients with isovaleric acidemia, the newborns 
treated with PGA, and control newborns are shown in Table 2. The value obtained by MRM 
with m/z 216 → 132 using DBS spiked with PG at the concentration of 50 nmol/ml was 
0.80 ± 0.05 nmol/ml (mean ± S.D.; n=6). 
     The serum levels of IVG and isovalerylcarnitine of a patient with IVA diagnosed 
prenatally are shown in Fig. 3. The concentration of IVG was markedly high (8.7 nmol/ml) 
in his first day of life and higher than that of isovalerylcarnitine. It reached the highest value 
two days after birth then decreased. The levels of isovalerylcarnitine exceeded those of IVG 
after carnitine therapy. 
 
4. Discussion 
     Diagnosis of IVA was classically based on the detection of massive excretion of a 
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series of isovaleryl-CoA metabolites, including IVG, in the urine of symptomatic patients, 
by the use of GC-MS. However, recent application of MS-MS to newborn screening has 
brought a new era when the majority of patients with IVA are diagnosed pre-
symptomatically through newborn screening in the United States and several European 
countries [13]. In MS-MS newborn screening for IVA, the marker metabolite is C5-
acylcarnitine in DBS, which represents a mixture of isomers (isovalerylcarnitine, 2-
methylbutyrylcarnitine, and pivaloylcarnitine), and cannot be measured separately by flow-
injection ESI-MS-MS. Thus, the newborns with elevated C5-acylcarnitine in DBS have to 
be evaluated further by GC-MS analysis of urine specimens even though elevated C5-
acylcarnitine in symptomatic infants, determined by MS-MS, is a diagnostic indication of 
IVA [14]. 
     Pivaloylcarnitine excretion in humans after PGA treatment was reported using GC-
MS and fast-atom bombardment MS in 1987 [15]. A false-positive result for IVA in 
newborn screening by MS-MS was first reported in Argentina in 1998; the newborn was 
breast-fed by a mother treated with PGA [16]. We have been disturbed by a lot of false-
positive results due to PVA administration to newborns since the start of our pilot study of 
MS-MS newborn screening in 1997 [6]. 
     In the present study, we have shown that the concentrations of IVG in DBS and 
serum specimens can be determined accurately by flow-injection ESI-MS-MS, where the 
interference by PG was negligible. The proposed structural formulae of product ions of m/z 
132 and m/z 142 are shown in Fig. 4. It is thought that the low intensity of product ion of 
m/z 132 derived from quasi-molecular ion of derivatized PG may be due to the preferential 
formation of product ion of m/z 198 through the loss of H2O. 
     Although the sensitivity was not high enough to determine the exact IVG levels in 
control newborns based on the noise intensities, our tentative IVG cut-off value of 0.5 
nmol/ml for screening of IVA patients was adopted, based on the data shown in Table 2. In 
our IVA patients with classic forms, the DBS levels of IVG were much higher than our cut-
off value and higher than those of C5-acylcarnitine. In our patient with the severe neonatal-
onset type, the IVG levels in serum specimens were markedly high at 21.2 nmol/ml in his 
early newborn period, even under intravenous glucose infusion. On the other hand, in our 
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patient with a milder type of IVA, the DBS concentration of IVG was 2/3 of that of C5-
acylcarnitine, and the lowest level of newborn DBS C5-acylcarnitine in IVA patients with a 
mild biochemical form was reported to be 0.8 nmol/ml [4]. Thus, our cut-off value should 
be reconfirmed in our future analysis. 
     We are now using our method to determine IVG in DBS in a second-tier analysis of 
the cases with high C5-acylcarnitine since we are measuring acylcarnitines and amino acids 
in DBS without derivatization in routine MS-MS newborn screening. However, the present 
methods can be applied to the routine screening using derivatized samples although the 
sensitivity of the instrument might be crucial. 
     We have shown the possible interference of another isomer of MBG, which is 
detected in the urine of patients with a very rare disorder of short/branched-chain acyl-CoA 
dehydrogenase deficiency [17]. It is reported that the levels of MBG in urine and C5-
acylcarnitine in DBS of the patients with this disorder were as low as those of IVG and C5-
acylcarnitine in the patients with a mild biochemical form of IVA. Thus, the patients with 
this disorder may be identified based on the increased levels of IVG determined by the 
present method, which indicates that urinary organic acid analysis is necessary as a 
confirmatory test in the case of high IVG in DBS. 
     In conclusion, the present method is useful to eliminate the false-positive results due 
to antibiotics use in MS-MS newborn screening for isovaleric acidemia. 
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Fig. 1. Mass spectra of the product ions derived from quasi-molecular ions ([M+H]+) of 
butyrated isovalerylglycine [A], 2-methylbutyrylglycine [B] and pivaloylglycine [C]. The 
intensity of product ion m/z 132 was high in [A] or [B], but very low in [C]. 
 
Fig. 2. Multiple-reaction monitoring chromatograms in the measurements of DBS samples 
of a patient with isovaleric acidemia [A] and a newborn treated with pivalate-generating 
antibiotics [B]; m/z 216 → 132 for isovalerylglycine, m/z 218 → 134 for 
[2H2]isovalerylglycine, and m/z 216 → 142 for pivaloylglycine and isovalerylglycine. 
Quantification was performed using averaged intensities of the designated MRM ion set. 
The increased intensity of m/z 216 →  132 in [A] demonstrated the accumulated 
isovalerylglycine in a patient with isovaleric acidemia. 
 
Fig. 3. Serum levels of isovalerylglycine, isovalerylcarnitine, and free carnitine in a patient 
with isovaleric acidemia who was treated with intravenous infusion of glucose immediately 
after birth because of a prenatal diagnosis of this disease. The isovalerylglycine levels 
reached the highest value two days after birth then decreased. The levels of C5-
acylcarnitine exceeded those of isovalerylglycine after carnitine therapy. See text in regard 
to clinical information of this patient. 
 
Fig. 4. Proposed structural formulae of product ions of m/z 132 and m/z 142. In 
pivaloylglycine butylester, the preferential formation of ring-form product ion of m/z 198 
by the loss of H2O may cause the paucity of the formation of product ion m/z 132, as shown 
in Fig.1. 
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